JP2022507295A5 - - Google Patents

Info

Publication number
JP2022507295A5
JP2022507295A5 JP2021525789A JP2021525789A JP2022507295A5 JP 2022507295 A5 JP2022507295 A5 JP 2022507295A5 JP 2021525789 A JP2021525789 A JP 2021525789A JP 2021525789 A JP2021525789 A JP 2021525789A JP 2022507295 A5 JP2022507295 A5 JP 2022507295A5
Authority
JP
Japan
Prior art keywords
seq
amino acid
acid sequence
variable domain
sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2021525789A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022507295A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2019/061278 external-priority patent/WO2020102422A1/en
Publication of JP2022507295A publication Critical patent/JP2022507295A/ja
Publication of JP2022507295A5 publication Critical patent/JP2022507295A5/ja
Withdrawn legal-status Critical Current

Links

JP2021525789A 2018-11-14 2019-11-13 治療用SIRPα抗体 Withdrawn JP2022507295A (ja)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US201862767509P 2018-11-14 2018-11-14
US62/767,509 2018-11-14
US201962820718P 2019-03-19 2019-03-19
US62/820,718 2019-03-19
US201962886872P 2019-08-14 2019-08-14
US62/886,872 2019-08-14
US201962931746P 2019-11-06 2019-11-06
US62/931,746 2019-11-06
PCT/US2019/061278 WO2020102422A1 (en) 2018-11-14 2019-11-13 THERAPEUTIC SIRPα ANTIBODIES

Publications (2)

Publication Number Publication Date
JP2022507295A JP2022507295A (ja) 2022-01-18
JP2022507295A5 true JP2022507295A5 (cg-RX-API-DMAC7.html) 2022-11-21

Family

ID=70730617

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021525789A Withdrawn JP2022507295A (ja) 2018-11-14 2019-11-13 治療用SIRPα抗体

Country Status (8)

Country Link
US (2) US11202828B2 (cg-RX-API-DMAC7.html)
EP (1) EP3880239A4 (cg-RX-API-DMAC7.html)
JP (1) JP2022507295A (cg-RX-API-DMAC7.html)
CN (1) CN113573728A (cg-RX-API-DMAC7.html)
AU (1) AU2019380503A1 (cg-RX-API-DMAC7.html)
BR (1) BR112021009325A2 (cg-RX-API-DMAC7.html)
CA (1) CA3119748A1 (cg-RX-API-DMAC7.html)
WO (1) WO2020102422A1 (cg-RX-API-DMAC7.html)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PH12018550160B1 (en) 2016-04-14 2024-07-03 Ose Immunotherapeutics NEW ANTI-SIRPa ANTIBODIES AND THEIR THERAPEUTIC APPLICATIONS
JOP20190009A1 (ar) 2016-09-21 2019-01-27 Alx Oncology Inc أجسام مضادة ضد بروتين ألفا منظم للإشارات وطرق استخدامها
WO2019183266A1 (en) 2018-03-21 2019-09-26 ALX Oncology Inc. Antibodies against signal-regulatory protein alpha and methods of use
CN112574310B (zh) * 2020-12-11 2023-05-05 浙江博锐生物制药有限公司 抗SIRPα抗体及其用途
US20240101716A1 (en) * 2020-12-18 2024-03-28 La Nova Medicines Development Co., Ltd. BISPECIFIC ANTIBODIES TARGETING SIRPa AND PD-L1
WO2022247933A1 (zh) * 2021-05-28 2022-12-01 百奥泰生物制药股份有限公司 抗SIPRα抗体及其应用
AU2022284373A1 (en) * 2021-06-04 2024-01-04 Boehringer Ingelheim International Gmbh Anti-sirp-alpha antibodies
CN113956363B (zh) 2021-10-13 2023-03-31 宜明昂科生物医药技术(上海)股份有限公司 靶向cd47和cd24的重组融合蛋白及其制备和用途
CN117447592B (zh) * 2022-07-26 2024-05-28 北京东方百泰生物科技股份有限公司 一种抗Siglec-15单克隆抗体、其抗原结合片段及其应用
CN115819586B (zh) * 2022-10-13 2023-10-31 珠海市丽珠单抗生物技术有限公司 抗人SIRPα单克隆抗体及其用途
WO2024105180A1 (en) 2022-11-16 2024-05-23 Boehringer Ingelheim International Gmbh Predictive efficacy biomarkers for anti-sirpa antibodies
JP2026512425A (ja) 2023-03-30 2026-04-16 オーエスイー・イミュノセラピューティクス 免疫細胞増強分子の発現のための活性化免疫細胞に標的化された脂質ベースのナノ粒子及びその使用
WO2024200820A1 (en) 2023-03-30 2024-10-03 Ose Immunotherapeutics Method of synthesis of targeted lipid nanoparticle and uses thereof
WO2024220895A1 (en) * 2023-04-20 2024-10-24 Twist Bioscience Corporation Antibodies and variant nucleic acid libraries for sirp-alpha
CN116514980B (zh) * 2023-04-23 2025-12-16 杭州美赛生物医药科技有限公司 抗SIRPα抗体及其应用
CN118047874B (zh) * 2024-02-19 2025-02-18 中科德佑(山西)生物科技有限公司 一种双特异性抗体及其与t细胞在制备治疗肿瘤药物中的应用
CN118791601B (zh) * 2024-07-24 2025-11-14 苏州大学 一株可改善结核分枝杆菌耐药性的抗Rv0340单克隆抗体及其应用

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU4128089A (en) * 1988-09-15 1990-03-22 Rorer International (Overseas) Inc. Monoclonal antibodies specific to human epidermal growth factor receptor and therapeutic methods employing same
PH12013501137A1 (en) * 2010-12-08 2021-06-02 Abbvie Stemcentrx Llc Novel modulators and methods of use
MX350335B (es) * 2011-08-17 2017-09-04 Univ California Anticuerpos que enlazan alfa-v beta-8 integrina.
HRP20190122T1 (hr) * 2011-11-16 2019-03-08 Adrenomed Ag Protutijelo protiv adrenomedulina (adm) ili fragment protutijela protiv adm ili okosnica ne-ig protiv adm, namijenjeni reguliranju ravnoteže tekućina kod pacijenta s kroničnom ili akutnom bolešću
BR112014017814A8 (pt) 2012-01-20 2017-07-11 Genzyme Corp Anticorpos anti-cxcr3
CN116425875A (zh) * 2015-09-18 2023-07-14 安驰肿瘤公司 治疗性cd47抗体
JOP20190009A1 (ar) * 2016-09-21 2019-01-27 Alx Oncology Inc أجسام مضادة ضد بروتين ألفا منظم للإشارات وطرق استخدامها
KR102642385B1 (ko) 2017-02-06 2024-03-04 오리오니스 바이오사이언시스 엔브이 표적화된 키메라 단백질 및 이의 용도
PT3443010T (pt) * 2017-02-17 2024-10-21 Ose Immunotherapeutics Novos anticorpos anti-sirpa e suas aplicações terapêuticas
JP7160833B2 (ja) * 2017-04-13 2022-10-25 サイロパ ビー.ブイ. 抗sirpアルファ抗体

Similar Documents

Publication Publication Date Title
US11858991B2 (en) LAG-3-binding molecules and methods of use thereof
US11202828B2 (en) Therapeutic SIRP-α antibodies
JP6955507B2 (ja) Pd‐1及びctla‐4との免疫応答性を有する二重特異性並びにその使用方法
US20220025050A1 (en) Bifunctional molecule directed against human pd-1
US11167029B2 (en) Combination of a CD30XCD16 antibody with a PD-1 antagonist for therapy
JP2019500892A5 (cg-RX-API-DMAC7.html)
KR20180093127A (ko) Pd-1-결합 분자 및 그것의 사용 방법
JP2019500891A5 (cg-RX-API-DMAC7.html)
RU2018126297A (ru) Антитела, нацеленные на cd32b, и способы их применения
JP7480307B2 (ja) 免疫細胞関与効果を調節するための手段および方法
JP2023543896A5 (cg-RX-API-DMAC7.html)
US20230279108A1 (en) Therapeutic sirp-alpha antibodies
EP4304724A1 (en) Combination therapy of pd-1-targeted il-2 variant immunoconjugate and anti-tyrp1/anti-cd3 bispecific antibodies
WO2023147331A1 (en) Bispecific molecule with tunable affinity to a targetted antigen
JP2023517889A5 (cg-RX-API-DMAC7.html)
JP7378567B2 (ja) Lag‐3結合分子及びその使用方法
BR112017026330B1 (pt) Molécula de ligação de lag-3 que compreende um domínio de ligação a lag-3 capaz de se ligar tanto ao lag-3 humano quanto ao lag-3 de macaco cynomolgus